Section Arrow
Quote
VRCA.NASDAQ
- Verrica Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/04/09 05:22 EDT
Pre Market
Last
 --
-- (--)
Bid
2.35
Ask
6.9
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 5.82
0 (0.00%)
Day High 
6.15 
Prev. Close
5.82 
1-M High
6.56 
Volume 
119.02K 
Bid
2.35
Ask
6.9
Day Low
5.82 
Open
5.96 
1-M Low
4.245 
Market Cap 
93.06M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.07 
20-SMA 5.47 
50-SMA 5.89 
52-W High 9.8212 
52-W Low 3.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.68/-1.41
Enterprise Value
93.95M
Balance Sheet
Book Value Per Share
1.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.58M
Operating Revenue Per Share
0.54
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1831+0.0201+12.33%-- 
Pre Market 0.1642 -0.0189 -10.32%
VRAXVirax Biolabs Group Limited0.15+0.01+7.14%-- 
Pre Market 0.142 -0.008 -5.33%
ELABPmgc Holdings Inc4.5+1.05+30.43%0PE
Pre Market 4.47 -0.03 -0.67%
CUECue Biopharma0.2738+0.0856+45.48%-- 
Pre Market 0.2299 -0.0439 -16.03%
GERNGeron Corp1.71-0.03-1.72%-- 
Pre Market 1.7 -0.01 -0.58%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.